Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 763,100 shares, a drop of 95.2% from the March 31st total of 16,010,000 shares. Based on an average trading volume of 70,300 shares, the short-interest ratio is currently 10.9 days. Approximately 12.0% of the shares of the stock are sold short.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds have recently modified their holdings of the company. Avantax Advisory Services Inc. raised its position in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC raised its position in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 37,866 shares during the last quarter. Virtu Financial LLC raised its position in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after purchasing an additional 44,461 shares during the period. Finally, State Street Corp lifted its stake in shares of Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after purchasing an additional 43,700 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.

Seres Therapeutics Price Performance

Shares of NASDAQ MCRB traded down $0.20 during mid-day trading on Thursday, hitting $9.50. 43,184 shares of the stock traded hands, compared to its average volume of 156,444. Seres Therapeutics has a twelve month low of $7.18 and a twelve month high of $30.60. The company has a market cap of $82.82 million, a PE ratio of -41.30 and a beta of 2.54. The firm has a 50 day simple moving average of $12.45 and a two-hundred day simple moving average of $15.00.

Analysts Set New Price Targets

A number of brokerages have weighed in on MCRB. StockNews.com downgraded Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Seres Therapeutics in a report on Thursday, March 20th. Finally, The Goldman Sachs Group reduced their target price on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a report on Friday, March 14th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Seres Therapeutics has a consensus rating of "Hold" and a consensus price target of $80.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.